title: Implementation of a vaccine against Shigatoxin 2e in a piglet producing farm with problems of Oedema disease: case study.
abstract: Oedema disease is one of the major diseases in pigs during the nursery period. It is caused by Shigatoxin 2e producing strains ofEscherichia coli. In order to combat the disease, the metaphylactic use of colistin sulphate and zinc oxide is widely spread. Additionally, special feeding regimens such as the reduction of the amount of crude protein and the increase of the amount of crude fibre are applied. The goal of this study was to test the efficacy of a vaccine against Oedema disease caused by Shigatoxin 2e in a field trial on a farm with a history of Oedema disease in nursery pigs. The study was carried out on a Dutch farm with 600 sows and a one-week farrowing rhythm and lasted for the time of one year. During this time all piglets were vaccinated with 1 ml ECOPORC SHIGA at the average age of 4 days. The parameters Overall mortality, use of antimicrobials in general, calculated as defined daily dose per animal, use of colistin sulphate and the weight gain were evaluated for all nursery pigs and compared to historical data of animals from the same period of time directly prior to the study serving as a historical control group. The previous mortality in the nursery of 7.7% was significantly reduced to 1.3% after vaccination. The metaphylactic use of colistin sulphate during the nursery period was stopped during the study because no deaths due to Oedema disease had occurred anymore after beginning of vaccination. The defined daily dose per animal per month was significantly reduced from a mean of 1.050 in the year 2012 to a mean of 0.215 in the year 2013. The defined daily dose per animal per year was therefore relevantly reduced from 12.6 in 2012 to 2.6 in 2013. These results show that on this farm Oedema disease can not only be controlled successfully by vaccination but also that vaccination can significantly reduce the use of antimicrobials in the nursery period.
authors.affiliation: IDT Biologika GmbH, Am Pharmapark, 06861 Dessau-Rosslau, Germany.
authors.forename: Regine
authors.initials: R
authors.lastname: Fricke
authors.affiliation: IDT Biologika GmbH, Am Pharmapark, 06861 Dessau-Rosslau, Germany.
authors.forename: Olaf
authors.initials: O
authors.lastname: Bastert
authors.affiliation: IDT Biologika GmbH, Am Pharmapark, 06861 Dessau-Rosslau, Germany.
authors.forename: Verena
authors.initials: V
authors.lastname: Gotter
authors.affiliation: Dierenkliniek Hellendorn, Ommerweg 54, 7447 RG Hellendoorn-Nijverdal, Kragujevac, Netherlands.
authors.forename: Nico
authors.initials: N
authors.lastname: Brons
authors.affiliation: Dierenkliniek Hellendorn, Ommerweg 54, 7447 RG Hellendoorn-Nijverdal, Kragujevac, Netherlands.
authors.forename: Johan
authors.initials: J
authors.lastname: Kamp
authors.affiliation: IDT Biologika GmbH, Am Pharmapark, 06861 Dessau-Rosslau, Germany.
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Selbitz
keywords: EDEC; Oedema disease; Reduction of antimicrobial use; STEC; Shigatoxin 2e; Vaccine